Moderna shares are volatile Monday after the company provided updates on its business and pipeline at a healthcare conference ...
InvestorsHub on MSN
Moderna shares edge higher after company lifts revenue outlook
Moderna (NASDAQ:MRNA) shares rose about 1% on Monday morning after the biotechnology company increased its revenue outlook ...
Zacks Investment Research on MSN
Moderna (MRNA) soars 10.9%: Is further upside left in the stock?
Moderna MRNA shares soared 10.9% in the last trading session to close at $35.66. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...
I agree to the Terms of Use , Privacy Notice and Cookie Notice.
Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey ...
This stock is a great choice for cautious and aggressive investors.
In early January 2026, Moderna filed for marketing authorization of its investigational seasonal influenza vaccine mRNA-1010 ...
Moderna MRNA is set to report third-quarter 2025 earnings on Nov. 6, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $860 million and a loss of $2.15 per ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback